{"commentary":{"count":131,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":68,"podcast":58,"x_thread":4,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02475681\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ElevateTN","nct_id":"NCT02475681","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elevatetn-nct02475681. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ElevateTN","arms":[{"description":"Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.","label":"Arm A - Obinutuzumab in Combination with Chlorambucil","type":"ACTIVE_COMPARATOR"},{"description":"Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.","label":"Arm B - Acalabrutinib in Combination with Obinutuzumab","type":"EXPERIMENTAL"},{"description":"Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.","label":"Arm C - Acalabrutinib Monotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-09-15","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia"],"enrollment":{"count":535,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Acalabrutinib","type":"DRUG"},{"name":"Obinutuzumab","type":"DRUG"},{"name":"Chlorambucil","type":"DRUG"}],"last_update":"2026-08-25","lead_sponsor":"Acerta Pharma BV","official_title":"A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2019-02-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B","timeFrame":"IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months."}],"references":[{"citation":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11;146(11):1276-1285. doi: 10.1182/blood.2024024476.","pmid":"40198878","type":"DERIVED"},{"citation":"Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142.","pmid":"38598745","type":"DERIVED"},{"citation":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.","pmid":"32305093","type":"DERIVED"}],"start_date":{"date":"2015-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","url":"https://clinicaltrials.gov/study/NCT02475681"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elevatetn-nct02475681"}